摘要
随着广谱抗菌药物的广泛应用,多重耐药鲍曼不动杆菌不断出现,并已成为现代医疗体系的重大挑战。碳青霉烯类抗生素是治疗鲍曼不动杆菌感染最有效的药物之一。但碳青霉烯类耐药鲍曼不动杆菌也逐渐增多,使治疗药物的选择非常局限。联合用药在体外研究中显示出不同程度的协同作用,新型药物的开发也显得格外重要。
With the wide use of broad-spectrum antimicrobial agents, muhidrug-resistant acinetobacter baumannii appear constantly and the infection due to it become a significant challenge to modem heahhcare system. Carbapenem is one of the most effective drugs. However, carbapenem-resistant strains have now emerged around the world, which made the treatment options very limited. Combination therapy in vitro studies show different synergistic activities ,while probing for new agent is also very important.
出处
《医学综述》
2013年第21期3968-3970,共3页
Medical Recapitulate
关键词
多重耐药鲍曼不动杆菌
单药治疗
联合用药
新型药物
Muhidrug-resistant acinetobacter baumannii
Monotherapy
Drug combination
New agents
